Cabaletta Bio Targets 2027 Myositis BLA, Details Key Clinical Milestones & 1H26 Data
CABA has more than doubled off its 52-week low of $0.986.
Summary
Cabaletta Bio reported its fourth quarter and full year 2025 financial results, though specific financial figures were not provided in the release. More significantly, the company delivered a comprehensive business update detailing substantial progress in its rese-cel clinical development program. Key highlights include the registrational dermatomyositis (DM) and antisynthetase syndrome (ASyS) cohort for rese-cel being on track for a Biologics License Application (BLA) submission in 2027. Additionally, Cabaletta Bio announced multiple upcoming catalysts for the first half of 2026, including initial RESET-SLE™ data, initial clinical experience with automated Cellares manufacturing, and complete Phase 1/2 data from RESET-SSc™, RESET-SLE, and RESET-MG™ trials. These updates provide a clear and positive roadmap for pipeline advancement and potential value creation for this clinical-stage biotechnology company. Investors will be closely monitoring the anticipated clinical data readouts in 1H26 and further progress towards the 2027 BLA submission.
At the time of this announcement, CABA was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283M. The 52-week trading range was $0.99 to $3.78. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.